drugset / Trial / NCT01913535
Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression
Phase 2
Terminated
8 enrolled
Massachusetts General Hospital
Butler Hospital · collabNational Institute of Mental Health (NIMH) · collabRush University · collabTemple University · collabUniversity of Kansas · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is looking at the efficacy, rapidity, safety, and tolerability of two doses of oral CERC-501 for treating patients with treatment resistant depression who are taking an antidepressant that is not working for them.
Timeline
- Start
- 2013-09-12
- Primary completion
- 2016-01-22
- Completion
- 2016-01-22
Outcome
Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)
Stopped (Enrollment): “slow enrollment”
release “Statistical testing was not performed due to the early termination and small sample size.” avalotx.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aticaprant | Small molecule | 10 mg | Oral |
| Subject | Aticaprant | Small molecule | 20 mg | Oral |
Indications
No indication recorded.